Hangzhou Biotest Biotech Co Ltd

First-half 2026 reports from in vitro diagnostics companies listed on the STAR Market show sharp divergence, with Autobio Diagnostics, Biotest Biotech and Orient Gene posting lower net profit while Rendu Biotechnology saw a surge. Autobio Diagnostics' first-half revenue and net profit fell 8.77% and 61.48% respectively, to 392 million yuan and 51 million yuan. Second-quarter revenue and net profit dropped 11.11% and 55.58% year on year, which the company attributed to intensifying industry competition, foreign exchange losses and higher research and development expenses. Orient Gene and Biotest Biotech grew revenue but not profit. Orient Gene's net loss widened to 222 million yuan, down 36.26% year on year, while Biotest Biotech swung from profit to a loss of 16.55 million yuan, plunging 233.46% year on year. Both cited US dollar exchange losses. Rendu Biotechnology's revenue edged down 2.22% to 79.44 million yuan, but net profit attributable to the parent surged 369.86% year on year to 9.58 million yuan, and non-recurring net profit turned positive, mainly thanks to cost reduction and efficiency gains. Selling, administrative and research and development expenses fell 11.86%, 10.10% and 21.98% respectively. In addition, companies such as YHLO Biotech, HOB Biotech and Dian Diagnostics also achieved net profit growth, with Dian Diagnostics' net profit soaring 2,160% to 232 million yuan. However, for some companies the improvement in profit was driven mainly by cost reduction and efficiency gains and a narrowing of credit impairment losses. The industry remains in a deep adjustment cycle, with centralised procurement, medical insurance cost controls and exchange rate fluctuations continuing to affect corporate performance.

Botuo Biotech released its 2026 interim report. In the first half of the year, the company's operating revenue was 215 million yuan, up 5.6% year on year, but it posted a loss of 16.55 million yuan, down 233.5% year on year. Second-quarter operating revenue was 125 million yuan, up 8.6% year on year, while net profit attributable to the parent company was a loss of 6.34 million yuan, down 272.9% year on year. The company said the decline in net profit was mainly due to a significant increase in research and development expenses caused by greater investment in new product development, as well as exchange losses from the depreciation of the US dollar. As of the end of the second quarter, the company's total assets were 2.405 billion yuan, down 5.3% from the end of the previous year, and net assets attributable to the parent company were 2.141 billion yuan, down 9.7% from the end of the previous year. The company's main business, core competitiveness, and ability to continue as a going concern have not undergone major changes. During the reporting period, it launched multiple new drug testing and infectious disease testing products, and has obtained a total of 1,014 international certifications, including 848 European Union CE certificates.